[1]
Tursi, A. and Tiano, M. 2021. SARS-COV-2 infection might cause transient cutaneous lesions in IBD patients under treatment with adalimumab. Journal of Gastrointestinal and Liver Diseases. 30, 2 (Jun. 2021), 310-311. DOI:https://doi.org/10.15403/jgld-3572.